How much did Eli Lilly's stock rise after the announcement?

Eli Lilly's stock rose 4.5% after the new data was unveiled.

When will retatrutide be available on the market?

Eli Lilly has not announced a launch date; the drug is still in Phase 3 trials.

What competition does retatrutide face?

Retatrutide competes with drugs like Novo Nordisk's Wegovy and Eli Lilly's own Mounjaro.

Eli Lilly Shares Rise 4.5% on Promising Obesity Drug Data at ADA

Eli Lilly presented new clinical data for its obesity drug retatrutide at the ADA conference, sending shares up 4.5%.

June 8, 2026

2 min read

Source: InvestorsHub

Key Numbers

stock gain

4.5%

Eli Lilly and Company (NYSE:LLY) shares gained 4.5% after the pharmaceutical giant unveiled additional clinical data on its obesity treatment retatrutide during the American Diabetes Association (ADA) conference over the weekend.

The Product

Retatrutide is an investigational once-weekly obesity treatment targeting GIP, GLP-1, and glucagon receptors. The new data showed significant weight loss and improved glycemic control in patients with type 2 diabetes.

Pricing and Availability

Eli Lilly has not yet disclosed pricing or launch timeline. The drug is currently in Phase 3 clinical trials.

Competition

Retatrutide competes with other obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's own Mounjaro. If approved, it could become a strong contender in the growing obesity treatment market.

Potential Impact on the Company

Successful development of retatrutide could strengthen Eli Lilly's leadership in obesity care, potentially driving significant revenue growth. However, final trial results and regulatory approval remain uncertain.

Frequently Asked Questions

Retatrutide is an investigational once-weekly obesity treatment targeting GIP, GLP-1, and glucagon receptors.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.